Skip to main content
Equibles
MRKR logo

MRKR · Marker Therapeutics, Inc. · Metrics

Track MRKR — free

Use MRKR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MRKR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.15 -0.05 (-4.17%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt regarding our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which implies that we will continue to realize our assets and discharge our liabilities in the normal course of business. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$19.17M
Shares
16.67M

MRKR metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.15
Market cap
$19.17M

Price action

20 metrics
Price change (1W)
-3.2%
Price change (30D)
+8.1%
Price change (3M)
-12.4%
Price change (6M)
-11.1%
Price change (YTD)
-19.5%
Price change (1Y)
+31.9%
Trailing year
Price change (5Y)
—
52-week high
$2.19
52-week low
$0.85
Change from 52-week high
-45.2%
Change from 52-week low
+41.2%
Annualized volatility
81.5%
Annualized volatility (3M)
74.0%
Beta
1.1
RSI (14D)
44.4
Price vs SMA 50
-7.4%
Price vs SMA 200
-16.6%
Avg volume (3M)
67,999
Relative volume
0.8
Average dollar volume
$91,524

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
16.67M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.1×
reciprocal yield 19.7%
P / book
1.6
reciprocal yield 60.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-43.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-11-10

Profitability

9 metrics
Gross margin
—
Operating margin
-363.5%
Trailing 12 months
Net margin
-343.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$9.50M
Net income (TTM)
−$8.71M
Trailing 12 months
Diluted EPS (TTM)
$-0.35
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.01

Growth

11 metrics
Revenue growth YoY
+115.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.95M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.4%
Year over year · more shares
Revenue CAGR (3Y)
+0.3%
Revenue CAGR (5Y)
+48.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-71.6%
Return on assets
-59.7%
Debt / equity
—
Current ratio
6.0
EBITDA (TTM)
−$11.27M
Free cash flow (TTM)
—
Quick ratio
6.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$11.33M
Total assets
$14.59M
Total debt
$67,942

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$9.76M
Capital expenditures (TTM)
$251,678
R&D (TTM)
$8.81M
SG&A (TTM)
—
Stock compensation (TTM)
$518,567
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
35
13F filer change QoQ
-1
Institutional ownership
23.8%

Short interest

3 metrics
Short interest
0.8%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
31 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1094038 CUSIP 57055L206 13F (30d) 21 filings 21 filers Visit website Investor relations